© 2000 American Heart Association, Inc.
Reports |
Endothelial Cells of Hematopoietic Origin Make a Significant Contribution to Adult Blood Vessel Formation
From the Department of Pathology (J.R.C., W.E.K., E.W.R., R.A.S., D.F.B.-P.), University of Washington, Seattle, Wash; and Division of Clinical Research (P.J.M.), Fred Hutchinson Cancer Research Center, Seattle, Wash. Current affiliations: J.R.C., S.C. Johnson Research Center, Mayo Clinic Scottsdale, Scottsdale, Ariz; W.E.K., Department of Clinical Chemistry and Laboratory Medicine, University of Regensburg Medical School, Regensburg, Germany; and G.S., Department of Anatomy and Cell Biology, University of Iowa, Iowa City, Iowa.
Correspondence to Daniel F. Bowen-Pope, University of Washington, Department of Pathology, Box 357470, Health Sciences Center, Room D525, Seattle, WA 98195-7470. E-mail bp{at}u.washington.edu
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Granulation tissue formation is an example of new tissue development in an adult. Its rich vascular network has been thought to derive via angiogenic sprouting and extension of preexisting vessels from the surrounding tissue. The possibility that circulating cells of hematopoietic origin can differentiate into vascular endothelial cells (ECs) in areas of vascular remodeling has recently gained credibility. However, no quantitative data have placed the magnitude of this contribution into a physiological perspective. We have used hematopoietic chimeras to determine that 0.2% to 1.4% of ECs in vessels in control tissues derived from hematopoietic progenitors during the 4 months after irradiation and hematopoietic recovery. By contrast, 8.3% to 11.2% of ECs in vessels that developed in sponge-induced granulation tissue during 1 month derived from circulating hematopoietic progenitors. This recruitment of circulating progenitors to newly forming vessels would be difficult to observe in standard histological studies, but it is large enough to be encouraging for attempts to manipulate this contribution for therapeutic gain.
Key Words: hematopoietic stem cell • angiogenesis • endothelial cell
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
When the endothelium is removed from a segment of large artery, the denuded region is reendothelialized via migration and proliferation of endothelial cells (ECs) from the adjacent intact endothelium. Occasionally, islands of ECs are observed, possibly representing colonization of the artery wall by circulating progenitors that had attached and proliferated.1 However, these are essentially never observed after deendothelialization of the rat carotid artery,2 the most thoroughly evaluated model of reendothelialization, and their origin is uncertain. New vessels can develop in adult tissue, eg, during granulation tissue formation. In this case, it is usually believed that with the exception of leukocytes, the cells that constitute this highly vascularized tissue, including fibroblasts, smooth muscle cells, and ECs, arrive via the proliferation and migration of these cell types from the adjacent tissue. Contribution by circulating cells would be very difficult to recognize, however, unless the two possible sources of ECs could be distinguished by informative markers.
One source of circulating EC progenitors could be the hematopoietic system. During early development, hematopoiesis is closely associated with the formation of EC-lined spaces. Both angioblasts and embryonic hematopoietic progenitors express Flk-1, Tie-1, and CD34. Targeted disruption of the genes for Flk-13 and its ligand, vascular endothelial growth factor,4 specifically disrupts both hematopoietic and EC function during development. This suggested the existence of a "hemangioblast," which can give rise to both hematopoietic stem cells and ECs, and a cell with this potential has been isolated from embryoid bodies.5 Moreover, CD34+ stem cells from adult peripheral blood can reconstitute the hematopoietic system.6 If some of these circulating cells have the developmental capacity of hemangioblasts, they might, under appropriate conditions, differentiate into ECs rather than hematopoietic cells.
Marked cells of hematopoietic origin injected intravenously into host mice or rabbits have been identified as ECs in the developing collateral vessels of ischemic tissues but not in vessels in unaffected tissue.7 8 This demonstrates that circulating cells can participate in the formation of endothelium, but no quantitative data have been reported to put this contribution into a physiological perspective. We undertook the present study to determine whether circulating hematopoietic-derived EC progenitors make a biologically significant contribution to new vessels compared with other sources of ECs.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Preparation of Marked Hematopoietic Chimeras
In E16 to E17 embryos,
50% of cells in the
liver are involved in hematopoiesis. E16.5 wild-type embryos,
homozygous for the genomic globin/pBR322 marker and expressing the
Ly-5b allele, were obtained by Caesarean
section, and the livers were mechanically dissociated to provide cells
for tail vein injection into C57BL6/J Ly-5a
recipient mice that had been irradiated 24 hours before transplantation
to eliminate endogenous hematopoiesis. The chimeric mice were
used 90 days after injection, at which time the globin/pBR322-marked
cells had completely reconstituted the hematopoietic system. The Ly-5
marker was used together with markers for different hematopoietic
lineages to confirm by flow cytometry that the host hematopoietic
system had been eliminated and that donor hematopoietic cell types were
present at levels within the normal range (J.R.C., W.E.K., P.J.M.,
E.W.R., D.F.B.-P., P. Lindahl, N.L. Lin, V. Broudy, B. Swolin, R. Ross,
C. Betscholtz, unpublished data, 2000). The experimental protocol was
approved by the University of Washington Committee for Animal Care and
Use.
Evaluation of Hematopoietic Origin of
ECs
We evaluated sections from the center of the sponge.
The method for visualization of the integrated marker that identifies a
cell of hematopoietic origin has been described
elsewhere.9 10
Because the histological section does not always include the entire
nucleus, false-negatives arise when the nuclear cross section does not
include either of the two chromosomal globin marker loci. Because this
is affected by nuclear shape and orientation, we used tissue from
purebred (ie, nonchimeric) mice homozygous for the marker to determine
the false-negative rate (6%) characteristic of ECs. All data have been
corrected for this. Leukocytes associated with vessels were identified
with the panleukocyte marker CD45 using rat monoclonal anti-mouse CD45
(clone 30-F11, Pharmingen), followed by biotinylated rabbit anti-rat
IgG, then Vectastain elite ABC peroxidase (Vector), and visualized
using diaminobenzidine. Laminin was stained using rabbit anti-mouse
laminin (Collaborative Biomedical Products), followed by biotinylated
goat anti-rabbit IgG Vectastain elite ABC peroxidase (Vector), and
visualized using diaminobenzidine. ECs expressing von Willebrand factor
(vWF) were identified by treating sections with proteinase K, then
incubating with rabbit anti-human vWF (Dako), followed by biotinylated
goat anti-rabbit IgG (Vector), then Vectastain ABC alkaline phosphatase
(Vector), and visualized using Vector Red substrate (Vector). ECs
expressing platelet-endothelial cell adhesion molecule (PECAM) (CD31)
were identified by incubating with biotinylated rat anti-mouse CD31
(Pharmingen), followed by Vectastain ABC alkaline phosphatase (Vector),
and visualized using Vector Red substrate (Vector). In all cases, the
immunostained sections were counterstained with methyl green nuclear
stain. To evaluate the extent of interobserver variation in identifying
marked ECs, a series of micrographs of sections stained with each of
the three reagent sets was separately scored by three of the coauthors.
The values differed by 2% or
less.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
To quantitate the contribution of circulating hematopoietic EC progenitors to new vessel formation, we prepared mouse hematopoietic chimeras in which cells derived from the hematopoietic system were marked by an integrated DNA marker detected as an unambiguous dark nuclear dot by nonisotopic in situ hybridization with a digoxigenin-labeled probe against the globin/pBR322 sequence.9 Because detection does not involve gene expression, this avoids possible effects of differentiation on marker expression.
To initiate granulation tissue formation, we implanted four small sponges under the skin on the back.10 By evaluating only tissue that developed within the sponge, we could specifically evaluate the contribution of marked cells to newly formed vessels. Four weeks later, we killed the mice and removed the sponges, along with samples of uninvolved skin, aorta, and brain. Tissues were fixed with methyl Carnoy’s fixative, embedded, sectioned, and evaluated by nonisotopic in situ hybridization to visualize the marker of hematopoietic origin and by immunohistochemical staining to identify cell type.9 10
We identified ECs in vessels of all sizes using three sets
of criteria, illustrated in the
Figure
:
(1) flattened cells on the luminal side of the basement membrane
(identified by immunostaining for laminin) that were negative for
expression of the panleukocyte marker CD45 (panel A); (2) flattened
vWF-positive cells surrounding a lumen (panel C); and (3)
PECAM-positive cells surrounding a lumen (panel E). The three methods
for identifying ECs detected somewhat different numbers of ECs per
optical field, but the percentage of these that were positive for the
globin marker of hematopoietic origin were very similar: 8.3% to
11.2% (panels B, D, and F). By contrast, the percentage of marked ECs
in normal tissues was only 0.2% to 1.4%. These results demonstrate
that circulating cells of hematopoietic origin make a significant
contribution to the endothelium of new vessels, and that these
hematopoietic-derived ECs were not different from ECs of host tissue
origin in expression of any of the EC markers
evaluated.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The recruitment of circulating hematopoietic-derived EC progenitors to newly forming vessels is small enough in magnitude to explain how this source of ECs might have been overlooked in histological studies but large enough to be encouraging for attempts to manipulate this contribution for therapeutic gain. Isner’s group has demonstrated that the number of circulating progenitors can be augmented by ischemia and granulocyte/macrophage colony-stimulating factor.11 This augmentation will clearly be important for maximizing the contribution of circulating progenitors to new vessel formation. In addition, this pathway must also be regulated at the level of the destination tissue, because the contribution of hematopoietic progenitors appears to be greatly augmented at sites of new vessel formation. Consistent with earlier studies,7 8 we found that marked hematopoietic progenitors did not make significant contributions to the endothelium of blood vessels in stable adult tissue, even during 4 months, 4-fold longer than the time during which the granulation tissue formed.
In future studies, it will be important to determine the mechanisms that specifically recruit progenitors to newly forming vessels. Are specific adhesion molecules upregulated that help localize the circulating progenitors, or is the enhancement due to an increased propensity of progenitors to differentiate into ECs in new, but not mature, vessels? Do the progenitors arrive in the tissue and then coalesce into vessels as in vasculogenesis, or are they recruited by attachment to, and integration into, the growing tips or shafts of existing vessels extending via angiogenic mechanisms?
|
Acknowledgments |
|---|
This research was supported by National Institutes of Health Grants HL03174 (to D.B.-P.) and HL18645 (to E.W.R.). We thank Russell Ross (died 3/18/99) for holding us to the highest critical standards in the interpretation of these results.
Received August 14, 2000; revision received September 14, 2000; accepted September 28, 2000.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
-
Shi
Q, Rafii S, Wu MH, Wijelath ES, Yu C, Ishida A, Fujita Y, Kothari S,
Mohle R, Sauvage LR, Moore MA, Storb RF, Hammond WP. Evidence for
circulating bone marrow-derived endothelial cells.
Blood. 1998;92:362–367.
[Abstract/Free Full Text] - Reidy MA, Schwartz SM. Endothelial injury and regeneration, IV: endotoxin, a nondenuding injury to aortic endothelium. Lab Invest. 1983;48:25–34.[Medline] [Order article via Infotrieve]
- Shalaby F, Ho J, Stanford WL, Fischer KD, Schuh AC, Schwartz L, Bernstein A, Rossant J. A requirement for Flk1 in primitive and definitive hematopoiesis and vasculogenesis. Cell. 1997;89:981–990.[Medline] [Order article via Infotrieve]
- Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, KS OS, Powell-Braxton L, Hillan KJ, Moore MW. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 1996;380:439–442.[Medline] [Order article via Infotrieve]
- Choi K, Kennedy M, Kazarov A, Papadimitriou JC, Keller G. A common precursor for hematopoietic and endothelial cells. Development. 1998;125:725–732.[Abstract]
-
Brugger
W, Heimfeld S, Berenson RJ, Mertelsmann R, Kanz L. Reconstitution of
hematopoiesis after high-dose chemotherapy by autologous progenitor
cells generated ex vivo. N Engl J Med. 1995;333:283–287.
[Abstract/Free Full Text] -
Asahara
T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler
B, Schatteman G, Isner JM. Isolation of putative progenitor endothelial
cells for angiogenesis. Science. 1997;275:964–967.
[Abstract/Free Full Text] -
Asahara
T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M,
Magner M, Isner JM. Bone marrow origin of endothelial progenitor cells
responsible for postnatal vasculogenesis in physiological and
pathological neovascularization. Circ Res. 1999;85:221–228.
[Abstract/Free Full Text] - Crosby JR, Seifert RA, Soriano P, Bowen-Pope DF. Chimaeric analysis reveals role of PDGF receptors in all muscle lineages. Nat Genet. 1998;18:385–388.[Medline] [Order article via Infotrieve]
-
Crosby
JR, Tappan KA, Seifert RA, Bowen-Pope DF. Chimera analysis reveals that
fibroblasts and endothelial cells require platelet-derived growth
factor receptor ß expression for participation in reactive connective
tissue formation in adults but not during development. Am
J Pathol. 1999;154:1315–1321.
[Abstract/Free Full Text] - Takahashi T, Kalka C, Masuda H, Chen D, Silver M, Kearney M, Magner M, Isner JM, Asahara T. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med. 1999;5:434–438.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  K. Iohara, L. Zheng, H. Wake, M. Ito, J. Nabekura, H. Wakita, H. Nakamura, T. Into, K. Matsushita, and M. Nakashima A Novel Stem Cell Source for Vasculogenesis in Ischemia: Subfraction of Side Population Cells from Dental Pulp Stem Cells, September 1, 2008; 26(9): 2408 - 2418. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Zampetaki, J. P. Kirton, and Q. Xu Vascular repair by endothelial progenitor cells Cardiovasc Res, June 1, 2008; 78(3): 413 - 421. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Kalka and I. Baumgartner Gene and stem cell therapy in peripheral arterial occlusive disease Vascular Medicine, May 1, 2008; 13(2): 157 - 172. [Abstract] [PDF]
|
|
|
|
 |
|
 Y. Tayyareci, M. Sezer, B. Umman, S. Besisik, A. Mudun, Y. Sanli, A. Oncul, N. Gurses, D. Sargin, M. Meric, et al. Intracoronary Autologous Bone Marrow-Derived Mononuclear Cell Transplantation Improves Coronary Collateral Vessel Formation and Recruitment Capacity in Patients With Ischemic Cardiomyopathy: A Combined Hemodynamic and Scintigraphic Approach Angiology, May 1, 2008; 59(2): 145 - 155. [Abstract] [PDF]
|
|
|
|
 |
|
 K. Asosingh, M. A. Aldred, A. Vasanji, J. Drazba, J. Sharp, C. Farver, S. A.A. Comhair, W. Xu, L. Licina, L. Huang, et al. Circulating Angiogenic Precursors in Idiopathic Pulmonary Arterial Hypertension Am. J. Pathol., March 1, 2008; 172(3): 615 - 627. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Tang, J. Lu, J. P. Walterscheid, H.-H. Chen, D. A. Engler, T. Sawamura, P.-Y. Chang, H. J. Safi, C.-Y. Yang, and C.-H. Chen Electronegative LDL circulating in smokers impairs endothelial progenitor cell differentiation by inhibiting Akt phosphorylation via LOX-1 J. Lipid Res., January 1, 2008; 49(1): 33 - 47. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kumin, M. Schafer, N. Epp, P. Bugnon, C. Born-Berclaz, A. Oxenius, A. Klippel, W. Bloch, and S. Werner Peroxiredoxin 6 is required for blood vessel integrity in wounded skin J. Cell Biol., November 19, 2007; 179(4): 747 - 760. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.-H. Chang, T. Chan-Ling, E. L. McFarland, A. Afzal, H. Pan, L. C. Baxter, L. C. Shaw, S. Caballero, N. Sengupta, S. L. Calzi, et al. IGF binding protein-3 regulates hematopoietic stem cell and endothelial precursor cell function during vascular development PNAS, June 19, 2007; 104(25): 10595 - 10600. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Asosingh, S. Swaidani, M. Aronica, and S. C. Erzurum Th1- and Th2-Dependent Endothelial Progenitor Cell Recruitment and Angiogenic Switch in Asthma J. Immunol., May 15, 2007; 178(10): 6482 - 6494. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Nishiwaki, M. Yoshida, H. Iwaguro, H. Masuda, N. Nitta, T. Asahara, and M. Isobe Endothelial E-Selectin Potentiates Neovascularization via Endothelial Progenitor Cell-Dependent and -Independent Mechanisms Arterioscler. Thromb. Vasc. Biol., March 1, 2007; 27(3): 512 - 518. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Shantsila, T. Watson, and G. Y.H. Lip Endothelial Progenitor Cells in Cardiovascular Disorders J. Am. Coll. Cardiol., February 20, 2007; 49(7): 741 - 752. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Lokmic, F. Stillaert, W. A. Morrison, E. W. Thompson, and G. M. Mitchell An arteriovenous loop in a protected space generates a permanent, highly vascular, tissue-engineered construct FASEB J, February 1, 2007; 21(2): 511 - 522. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. C. Schatteman, M. Dunnwald, and C. Jiao Biology of bone marrow-derived endothelial cell precursors Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H1 - H18. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. W. van Laake, R. Hassink, P. A. Doevendans, and C. Mummery Heart repair and stem cells J. Physiol., December 1, 2006; 577(2): 467 - 478. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Capoccia, R. M. Shepherd, and D. C. Link G-CSF and AMD3100 mobilize monocytes into the blood that stimulate angiogenesis in vivo through a paracrine mechanism Blood, October 1, 2006; 108(7): 2438 - 2445. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.J.M. Loomans, H. Wan, R. de Crom, R. van Haperen, H.C. de Boer, P.J.M. Leenen, H.A. Drexhage, T.J. Rabelink, A.J. van Zonneveld, and F.J.T. Staal Angiogenic Murine Endothelial Progenitor Cells Are Derived From a Myeloid Bone Marrow Fraction and Can Be Identified by Endothelial NO Synthase Expression Arterioscler. Thromb. Vasc. Biol., August 1, 2006; 26(8): 1760 - 1767. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. R. Shepherd, D. R. Enis, F. Wang, Y. Suarez, J. S. Pober, and J. S. Schechner Vascularization and engraftment of a human skin substitute using circulating progenitor cell-derived endothelial cells FASEB J, August 1, 2006; 20(10): 1739 - 1741. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. DiFabio, G. R. Thomas, L. Zucco, M. A. Kuliszewski, B. M. Bennett, M. J. Kutryk, and J. D. Parker Nitroglycerin Attenuates Human Endothelial Progenitor Cell Differentiation, Function, and Survival J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 117 - 123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Li, E. E. Sharpe, A. B. Maupin, A. A. Teleron, A. L. Pyle, P. Carmeliet, and P. P. Young VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization FASEB J, July 1, 2006; 20(9): 1495 - 1497. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. P. Fadini, M. Schiavon, M. Cantini, I. Baesso, M. Facco, M. Miorin, M. Tassinato, S. V. d. Kreutzenberg, A. Avogaro, and C. Agostini Circulating Progenitor Cells Are Reduced in Patients with Severe Lung Disease Stem Cells, July 1, 2006; 24(7): 1806 - 1813. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. E. Sharpe III, A. A. Teleron, B. Li, J. Price, M. S. Sands, K. Alford, and P. P. Young The Origin and in Vivo Significance of Murine and Human Culture-Expanded Endothelial Progenitor Cells Am. J. Pathol., May 1, 2006; 168(5): 1710 - 1721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Zentilin, S. Tafuro, S. Zacchigna, N. Arsic, L. Pattarini, M. Sinigaglia, and M. Giacca Bone marrow mononuclear cells are recruited to the sites of VEGF-induced neovascularization but are not incorporated into the newly formed vessels Blood, May 1, 2006; 107(9): 3546 - 3554. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Sheridan, D. Rice, P. S. Hiscott, D. Wong, and D. L. Kent The Presence of AC133-Positive Cells Suggests a Possible Role of Endothelial Progenitor Cells in the Formation of Choroidal Neovascularization. Invest. Ophthalmol. Vis. Sci., April 1, 2006; 47(4): 1642 - 1645. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. Suuronen, S. Wong, V. Kapila, G. Waghray, S. C. Whitman, T. G. Mesana, and M. Ruel Generation of CD133+ cells from CD133- peripheral blood mononuclear cells and their properties Cardiovasc Res, April 1, 2006; 70(1): 126 - 135. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Anghelina, P. Krishnan, L. Moldovan, and N. I. Moldovan Monocytes/Macrophages Cooperate with Progenitor Cells during Neovascularization and Tissue Repair: Conversion of Cell Columns into Fibrovascular Bundles Am. J. Pathol., February 1, 2006; 168(2): 529 - 541. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Werner and G. Nickenig Influence of Cardiovascular Risk Factors on Endothelial Progenitor Cells: Limitations for Therapy? Arterioscler. Thromb. Vasc. Biol., February 1, 2006; 26(2): 257 - 266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Sainz, A. Al Haj Zen, G. Caligiuri, C. Demerens, D. Urbain, M. Lemitre, and A. Lafont Isolation of "Side Population" Progenitor Cells From Healthy Arteries of Adult Mice Arterioscler. Thromb. Vasc. Biol., February 1, 2006; 26(2): 281 - 286. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K Herbrig, S Haensel, U Oelschlaegel, F Pistrosch, S Foerster, and J Passauer Endothelial dysfunction in patients with rheumatoid arthritis is associated with a reduced number and impaired function of endothelial progenitor cells Ann Rheum Dis, February 1, 2006; 65(2): 157 - 163. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-S. Silvestre and B. I. Levy Molecular Basis of Angiopathy in Diabetes Mellitus Circ. Res., January 6, 2006; 98(1): 4 - 6. [Full Text] [PDF]
|
|
|
|
 |
|
 A. N. Patel, L. Geffner, R. F. Vina, J. Saslavsky, H. C. Urschel Jr, R. Kormos, and F. Benetti Surgical treatment for congestive heart failure with autologous adult stem cell transplantation: A prospective randomized study J. Thorac. Cardiovasc. Surg., December 1, 2005; 130(6): 1631 - 1638. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Tamaki, Y. Uchiyama, Y. Okada, T. Ishikawa, M. Sato, A. Akatsuka, and T. Asahara Functional Recovery of Damaged Skeletal Muscle Through Synchronized Vasculogenesis, Myogenesis, and Neurogenesis by Muscle-Derived Stem Cells Circulation, November 1, 2005; 112(18): 2857 - 2866. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Guleng, K. Tateishi, M. Ohta, F. Kanai, A. Jazag, H. Ijichi, Y. Tanaka, M. Washida, K. Morikane, Y. Fukushima, et al. Blockade of the Stromal Cell-Derived Factor-1/CXCR4 Axis Attenuates In vivo Tumor Growth by Inhibiting Angiogenesis in a Vascular Endothelial Growth Factor-Independent Manner Cancer Res., July 1, 2005; 65(13): 5864 - 5871. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sandri, V. Adams, S. Gielen, A. Linke, K. Lenk, N. Krankel, D. Lenz, S. Erbs, D. Scheinert, F. W. Mohr, et al. Effects of Exercise and Ischemia on Mobilization and Functional Activation of Blood-Derived Progenitor Cells in Patients With Ischemic Syndromes: Results of 3 Randomized Studies Circulation, June 28, 2005; 111(25): 3391 - 3399. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Awad, C. Jiao, N. Ma, M. Dunnwald, and G. C. Schatteman Obese Diabetic Mouse Environment Differentially Affects Primitive and Monocytic Endothelial Cell Progenitors Stem Cells, April 1, 2005; 23(4): 575 - 583. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. H. Bahlmann, K. de Groot, O. Mueller, B. Hertel, H. Haller, and D. Fliser Stimulation of Endothelial Progenitor Cells: A New Putative Therapeutic Effect of Angiotensin II Receptor Antagonists Hypertension, April 1, 2005; 45(4): 526 - 529. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Guthrie, L. M. Curtis, R. N. Mames, G. G. Simon, M. B. Grant, and E. W. Scott The nitric oxide pathway modulates hemangioblast activity of adult hematopoietic stem cells Blood, March 1, 2005; 105(5): 1916 - 1922. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Murasawa and T. Asahara Endothelial Progenitor Cells for Vasculogenesis Physiology, February 1, 2005; 20(1): 36 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Goligorsky Whispers and shouts in the pathogenesis of acute renal ischaemia Nephrol. Dial. Transplant., February 1, 2005; 20(2): 261 - 266. [Full Text] [PDF]
|
|
|
|
|
|
G. Schatteman Are Circulating CD133+ Cells Biomarkers of Vascular Disease? Arterioscler. Thromb. Vasc. Biol., February 1, 2005; 25(2): 270 - 271. [Full Text] [PDF]
|
|
|
|
|
|
O. M. Tepper, J. M. Capla, R. D. Galiano, D. J. Ceradini, M. J. Callaghan, M. E. Kleinman, and G. C. Gurtner Adult vasculogenesis occurs through in situ recruitment, proliferation, and tubulization of circulating bone marrow-derived cells Blood, February 1, 2005; 105(3): 1068 - 1077. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Fliser, K. de Groot, F. H. Bahlmann, and H. Haller Cardiovascular disease in renal patients--a matter of stem cells? Nephrol. Dial. Transplant., December 1, 2004; 19(12): 2952 - 2954. [Full Text] [PDF]
|
|